ClinicalTrials.gg
TerminatedNCT02762253Updated May 5, 2016

Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross-Linking in Eyes With Keratoconus.

A Phase 2 interventional study of Riboflavin drops in Keratoconus, sponsored by Nvision Laser Eye Centers. Terminated at 11 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2016-05-05.

Sponsored by Nvision Laser Eye Centers · Phase 2, Interventional, and Treatment

Why this study was terminated
No IND submitted to the FDA

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
320
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing riboflavin in Keratoconus — 5 open to participants now, 8 under way, 7 of them phase 3. Riboflavin · Keratoconus.

Enrollment
8th of 23
320 · median 170
Started
2012
with 2 others
Phase 2
3 of 23
none open now
Registered
15th of 23
by date
Lead sponsor
1 of 23
Nvision Laser Eye Centers

Among the 23 studies testing riboflavin in Keratoconus, this one is the 8th largest by enrollment, is one of 3 that started in 2012, is one of 3 in phase 2, and was the 15th registered.

Keratoconus

313 studies on the registry are indexed under Keratoconus; 56 are open to participants now.

Browse Keratoconus studies →

Open to participants now

5 of the 23 studies testing riboflavin in Keratoconus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About riboflavin

Riboflavin: first FDA approval 1953 (M.V.I.-12 ADULT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Keratoconus studies recruiting now, 21 (57%) set no upper age limit and 11 (30%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing riboflavin in Keratoconus, or all of them as a file.
02

Study summary

This study is being conducted to assess the safety and effectiveness of photochemically induced collagen cross- linking (CCL) at irradiance of 18mW/cm2 in eyes with Keratoconus and Ecstasia.

Read the detailed description

Riboflavin drops are used every 2 minutes for 30+ minutes until the corneal stroma is saturated with Riboflavin as evidenced by observing Riboflavin in the Anterior chamber. Two arms in the study, one uses Riboflavin with Epithelium on and the other with Epithelium off. Once it is observed that the Riboflavin has penetrated the stroma and is seen in the anterior chamber, the cornea is exposed to Ultraviolet light at an irradiance level of 18mW/cm2 for 5 minutes. A contact lens is applied until the epithelium has fully healed in 3 to 5 days. The study is for 6 months. The corneal curvature as well as the uncorrected and best corrected vision and corneal thickness are evaluated pre-operatively and at 6 months. The primary variable that is assessed to determine the efficacy of the drug is the Kmax - Steep corneal curvature. Secondary effectiveness criteria are uncorrected and best corrected vision and corneal thickness. adverse events are also monitored.

03

Conditions studied

  • Keratoconus

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

INCLUSION CRITERIA GENERAL:

  1. 12 years of age or older
  2. Signed written
  3. Willingness and ability to comply with schedule for follow-up visits
  4. Contact lens removal prior to evaluation and treatment
  5. Candidates must also have two of the following criteria:

    1. Presence of central or inferior steepening on the Pentacam or Orbscan map consistent with Keratoconus.
    2. Axial topography consistent with keratoconus.
    3. Steepest keratometry (Kmax) value of 47.00D

INCLUSION CRITERIA FOR ECTASIA:

History of having undergone a keratorefractive procedure and 2 of the following criteria:

  1. Steepening by topography, either Pentacam or Orbscan
  2. Thinning of cornea
  3. Shift in the position of thinnest portion of cornea
  4. Change in refraction with increasing myopia
  5. Development of myopic astigmatism
  6. Development of irregular astigmatism
  7. Loss of BSCVA

    EXCLUSION CRITERIA:

    I. Eyes classified as either normal or atypical normal 2. Corneal pachymetry 350 microns at the thinnest point measured by Pentacam in the eye to be treated 3. A history of chemical injury or delayed epithelial healing in the eye to be treated.

    1. Pregnancy (including plan to become pregnant) or lactation during the course of the study 5. A known sensitivity to study medications 6. Patients with nystagmus or any other condition that would prevent a steady gaze during the treatment 7. Inability to cooperate with diagnostic tests. 8. Patients with a concomitant condition that, in the investigator's opinion, would interfere with or prolong epithelial healing.
    1. Taking Vitamin C (ascorbic acid) supplements within 1 week of the cross-linking treatment.
    1. Patients who are unable to remain supine and tolerate a lid speculum for an extended period of time.

    -

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
320 participants (actual)

Study arms

  • Other
    Riboflavin drops - epithelium on or off

    Riboflavin is applied with Epithelium on or with it off. 6 months follow up to find out magnitude of Decrease in Kmax

    Drug: Riboflavin drops

Interventions

  • Riboflavin drops were used every 2 minutes for 30 minutes on the cornea then exposed to 5 minutes of Ultraviolet light at an intensity of 18mW/cm2

    Also known as: Rincolin

06

What researchers measure

Primary outcomes

  1. Keratometry

    The change in maximum keratometry (Kmax) from baseline will be evaluated at 6 months for all eyes. Data will be summarized using descriptive statistics.

    Time frame: 6 months

Secondary outcomes

  1. manifest refraction

    The change in manifest refraction at 6 months compared to pre op

    Time frame: 6 months

  2. Visual Acuity

    Change in BSCVA and UCVA compared to the baseline examination will be evaluated at 6 months postoperatively.

    Time frame: 6 months

  3. Central Pachymetry

    The change in central pachymetry (as measured by Pentacam) from baseline will be evaluated at 6 months postoperatively. Data will be summarized using descriptive statistics.

    Time frame: 6 months

07

Study locations

11 sites
  • NVISION Camarillo
    Camarillo, California 93010, United States
  • NVISION Sacramento
    Citrus Heights, California 95621, United States
  • NVISION Fullerton
    Fullerton, California 92831, United States
  • NVISION Laguna Hills
    Laguna Hills, California 92653, United States
  • NVISION Newport Beach
    Newport Beach, California 92660, United States
  • NVISION Ontario
    Ontario, California 91764, United States
  • NVISION La Jolla
    San Diego, California 92122, United States
  • Berg Feinfield Vision Center
    Sherman Oaks, California 91423, United States
  • NVISION Torrance
    Torrance, California 90505, United States
  • NVISION Las Vegas
    Las Vegas, Nevada 89119, United States
  • Teplick Custom Vision
    Beaverton, Oregon 97008, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2016
First posted
May 4, 2016
Start
Sep 2012
Primary completionActual
Apr 2016
CompletionActual
Apr 2016
Last update
May 5, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02762253
Lead sponsor
Nvision Laser Eye Centers
Responsible party
Sponsor
First posted
May 4, 2016
Start date
Sep 2012
Primary completion
Apr 2016
Completion
Apr 2016
Last update
May 5, 2016

Study contacts

tom s tooma, md
principal investigator · NVISION Eye Centers

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Riboflavin

Start the discussion